By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Puma Biotechnology 

10940 Wilshire Boulevard
Suite 600
Los Angeles  Caliornia   90024  U.S.A.
Phone: 310-443-4150 Fax: 310-443-4158


Company News
FDA's Shorten Review Time is a Bad Sign for Puma Biotech (PBYI)'s Controversial Cancer Drug 4/19/2017 6:20:24 AM
Puma Biotech (PBYI) Announces FDA Advisory Committee To Review Neratinib For The Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer 4/17/2017 9:23:30 AM
Caligor To Support Puma Biotech (PBYI)’s Expanded Access Program For PB272 (Neratinib) In The United States 4/13/2017 8:05:21 AM
Puma Biotech (PBYI) Presents Interim Results Of Phase Ib/II FB-10 Trial Of PB272 In Combination With Trastuzumab Emtansine (T-DM1) In HER2-Positive Metastatic Breast Cancer At The 2017 AACR Annual Meeting 4/3/2017 11:22:53 AM
Puma Biotech (PBYI) Presents Results From The Phase II SUMMIT Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer At The 2017 AACR Annual Meeting 4/3/2017 10:19:35 AM
Puma Biotech (PBYI) Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017 3/2/2017 10:52:27 AM
Puma Biotech (PBYI) Reports Fourth Quarter And Full Year 2016 Financial Results 3/2/2017 8:10:30 AM
Puma Biotech (PBYI) Provides Update On Review Of Marketing Authorisation Application For PB272 3/2/2017 8:05:07 AM
Puma Biotech (PBYI) Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients 1/6/2017 10:36:22 AM
Puma Biotech (PBYI) To Move Stock Exchange Listing To Nasdaq 12/20/2016 1:04:13 PM